QuidelOrtho Corporation (QDEL)
| Market Cap | 1.13B -33.9% |
| Revenue (ttm) | 2.66B -3.9% |
| Net Income | -1.21B |
| EPS | -17.81 |
| Shares Out | 68.19M |
| PE Ratio | n/a |
| Forward PE | 8.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,323 |
| Open | 16.70 |
| Previous Close | 16.68 |
| Day's Range | 16.20 - 16.93 |
| 52-Week Range | 9.92 - 35.58 |
| Beta | 0.69 |
| Analysts | Hold |
| Price Target | 20.50 (+23.64%) |
| Earnings Date | Jul 29, 2026 |
About QDEL
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or... [Read more]
Financial Performance
In 2025, QuidelOrtho's revenue was $2.73 billion, a decrease of -1.89% compared to the previous year's $2.78 billion. Losses were -$1.13 billion, -44.84% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for QDEL stock is "Hold." The 12-month stock price target is $20.5, which is an increase of 23.64% from the latest price.
News
Beyond Fentanyl: How the Drug Crisis Is Changing
SAN DIEGO, July 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science Bytes podcast examining how the drug ov...
QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of th...
QuidelOrtho price target raised to $18 from $13 at Citi
Citi raised the firm’s price target on QuidelOrtho (QDEL) to $18 from $13 and keeps a Neutral rating on the shares.
QuidelOrtho price target raised to $12 from $11 at JPMorgan
JPMorgan raised the firm’s price target on QuidelOrtho (QDEL) to $12 from $11 and keeps an Underweight rating on the shares. The firm updated the company’s model. Published first on…
QuidelOrtho puts point-of-care testing unit up for sale, FT reports
QuidelOrtho (QDEL), the company behind one of the most well-known rapid coronavirus tests, is putting up for sale its point-of-care testing arm, seeking a valuation of $1.5B as private equity…
QuidelOrtho surges 33% after FT says company looking to sell point-of-care arm
11:39 EDT QuidelOrtho (QDEL) surges 33% after FT says company looking to sell point-of-care arm
QuidelOrtho appoints Micah Young as CFO
QuidelOrtho (QDEL) appointed Micah Young as CFO, effective July 6. Young will succeed Joseph Busky, who previously announced his retirement as CFO and will serve in an advisory role to…
QuidelOrtho Appoints Micah Young as Chief Financial Officer
Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("Qu...
QuidelOrtho Transcript: AGM 2026
The meeting was held virtually, with a quorum established and all proposals—including director elections, executive compensation approval, and auditor ratification—passed by stockholders. Final results will be filed in a Form 8-K.
QuidelOrtho Transcript: Jefferies Global Healthcare Conference 2026
Significant cost reductions and organizational changes have set the stage for margin expansion and renewed growth, with new product launches and regional recoveries expected to drive performance in the second half. China faces a pricing reset, but underlying lab and immunohematology businesses remain strong.
QuidelOrtho Transcript: 46th Annual William Blair Growth Stock Conference
Diagnostic testing demand is rising due to demographic and healthcare trends, with a diversified portfolio and strong recurring revenue base. Recent innovation, including the NULEXA platform, and cost-saving initiatives support ongoing growth, margin expansion, and deleveraging plans.
QuidelOrtho Slides: 46th Annual William Blair Growth Stock Conference
QuidelOrtho has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing matern...
When Blood Compatibility Becomes a Pregnancy Risk
SAN DIEGO, May 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 58 of its Science Bytes podcast, focusing on hemolytic dis...
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its...
Hantavirus outbreak: these 3 stocks are poised to rip higher
The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed ...
QuidelOrtho price target lowered to $11 from $15 at JPMorgan
JPMorgan lowered the firm’s price target on QuidelOrtho (QDEL) to $11 from $15 and keeps an Underweight rating on the shares post the Q1 report. The firm cites weak respiratory…
QuidelOrtho price target lowered to $12 from $17 at UBS
UBS analyst Lu Li lowered the firm’s price target on QuidelOrtho (QDEL) to $12 from $17 and keeps a Neutral rating on the shares. The firm updated its model and…
QuidelOrtho downgraded to Hold from Buy at Jefferies
Jefferies analyst Tycho Peterson downgraded QuidelOrtho (QDEL) to Hold from Buy with a price target of $12.50, down from $35. The company reported a “disappointing” Q1 and provided a 2026…
QuidelOrtho price target lowered to $13 from $30 at Citi
Citi lowered the firm’s price target on QuidelOrtho (QDEL) to $13 from $30 and keeps a Neutral rating on the shares.
QuidelOrtho Earnings Call Transcript: Q1 2026
Q1 2026 results were impacted by a weak respiratory season and China headwinds, leading to lower revenue and margins, but core businesses and new product launches remain strong. Full-year guidance was lowered, with margin expansion and cash flow improvement expected in the second half.
QuidelOrtho Earnings release: Q1 2026
QuidelOrtho released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
QuidelOrtho Slides: Q1 2026
QuidelOrtho has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
QuidelOrtho Quarterly report: Q1 2026
QuidelOrtho has published its Q1 2026 quarterly earnings report on May 5, 2026.
QuidelOrtho reports adjusted Q1 EPS (4c), consensus 42c
Reports Q1 revenue $619.8M, consensus $659.17M. “Our first quarter results were in line with our preliminary revenue announcement and reflected a significantly weaker respiratory season and business d...